Vir Biotechnology was founded in 2016 by President and CEO Dr. George Scangos and Chief Scientific Officer Peter Thompson. Together they bring decades of experience in biotechnology drug discovery, development and commercialization. Expressing their deep conviction in the power of monoclonal antibodies to cure disease, George and Peter have driven Vir since day one. Over the past four years, Vir has assembled world-class scientific and commercial leadership, raised over $530M in venture capital, established strategic collaborations and partnerships, built state-of-the-art facilities and developed a promising pipeline of product candidates for large unmet medical needs.
